Lab Mistakes Hobble Cancer Studies But Scientists Slow to Take Remedies

1st Tuesday, 2012  |   Others  |  no comments

AMY DOCKSER MARCUS. Wall Street Journal. 20 April 2012
Last year, cancer researcher Robert Mandic got news no scientist wants to hear.
After publishing a paper on a rare head-and-neck cancer, he learned the cells he had been studying were instead cervical cancer. He notified the journal Oral Oncology, which retracted the article.
“To base something on wrong data is bad, so it needs to be reported and I did,” said Dr. Mandic, a researcher at the University Hospital Giessen and Marburg in Germany. “But it wasn’t pleasant to call.”
Dr. Mandic entered a largely secret fellowship of scientists whose work has been undermined by the contamination and misidentification of cancer cell lines used in research labs around the world.
Related Video
Hypnosis may stir images of stage magic and swinging pocket watches, but there’s growing evidence it can be useful for easing pain, relieving anxiet and relaxing patients before surgery. Melinda Beck has details on Lunch Break. Photo: Getty Images
Cancer experts seeking to solve the problem have found that a fifth to a third or more of cancer cell lines tested were mistakenly identified—with researchers unwittingly studying the wrong cancers, slowing progress toward new treatments and wasting precious time and money.
In hundreds of documented cases that undermine a broad swath of research, cancer samples that were supposed to be one type of tumor have turned out to be another, through either careless laboratory handling, mislabeling or other mistakes.

It is a problem hiding in plain sight. Warnings to properly test cancer cell lines have sounded since the 1960s, a decade after scientists started making human cancer cell lines.
But researchers who yelled loudest were mostly ignored by colleagues fearful such a mistake in their own labs would discredit years of work.
Leaders in the field say one of the biggest obstacles to finding a cancer cure may not be the many defenses nature affords malignancies, but the reluctance of scientists to address the problem.
“Screaming and shouting, it doesn’t do any good. No one takes any notice for reasons I don’t understand,” said John Masters, a professor of experimental pathology at University College London, UCL. “The whole ethos of science is to strive for the truth and produce a balanced argument about the evidence. Yet, all this crap is being produced.”
Dr. Masters said cell banks report that 20% of cell lines sent for inclusion in their repositories for use by researchers are improperly identified. He was co-chair of an international committee of scientists that released voluntary guidelines this year to begin solving the problem. They call for, among other measures, routine profiling of cell lines using a DNA technique employed in forensics called “short tandem repeats,” or STR.
Much of cancer research seeks answers to questions of basic biology, so the proper identification of cell lines may be less important, said Dr. Masters. But when seeking cancer treatment for a specific tumor, he said, such mistakes “are an utter waste of public money, charity money and time.”

Worse, he added, “It may be causing drugs to be used which are inappropriate for that particular type of cancer.”
Cancer research relies on cell lines that originate in patient tumors. The cells are usually grown in plastic containers and, with the proper nutrients, can live indefinitely in a laboratory. Scientists store them in freezers for years. The cells mimic particular kinds of tumors, giving researchers a way to understand what drives a disease or to test promising drug treatments.
It may take a year or more to find the right combination of nutrients to keep cancer cells growing. Once a line is established, scientists often share them with colleagues, who then grow them in their own labs. The problem is that many scientists don’t test the cells when shipping or receiving a batch.
The most famous and ubiquitous human cancer cell line was the first—an aggressive, fast-growing cervical cancer taken from Henrietta Lacks of Maryland before her death in 1951. It has been shared with scientists world-wide in the decades since, playing a broad role in medical research spanning polio to haemophilia.
The so-called HeLa cells, named for Ms. Lacks, also have taken over other cancer cell lines, many times unknown to researchers.
These mix-ups are maddeningly difficult to pinpoint: an improperly sterilized pipette, a lab worker momentarily distracted, a misread label or a typo on a record sheet.
Cell repositories in the U.S., U.K., Germany and Japan have estimated that 18% to 36% of cancer cell lines are incorrectly identified. Researchers at Glasgow University and CellBank Australia found more than 360 such mistaken cell lines, including 100 that turned out to be the late Ms. Lack’s cervical cancer cells.

“All of this sharing of cell lines, it’s a bit like having unprotected sex,” said David Tarin, a pathologist at the University of California, San Diego.
Dr. Tarin himself is at the center of a lingering debate over the true identity of a famous breast cancer cell line known as MDA-MB-435.
Dr. Tarin has spent 25 years working with that cell line—or so he thinks. A body of research suggests that MDA-MB-435 isn’t breast cancer; many scientists now believe the cells growing in labs and used in decades of research are melanoma.
The line originated at the M.D. Anderson Cancer Center in Houston, using cells from a 31-year-old woman who died in 1976, less than a year after she was diagnosed. The cell line was among the most widely used in metastatic breast cancer research.

In 2000, scientists at Stanford University, working in collaboration with the National Cancer Institute, started testing the 60 cell lines in the institute’s permanent collection.
Michael Eisen, then part of the Stanford team, said they found something surprising about the breast cancer cell line: genes that mimicked melanoma. “It stuck out as problematic,” said Dr. Eisen.
At the time, the scientists didn’t suspect contamination. They thought the breast cancer patient also might have had undiagnosed melanoma.
Other scientists, following up on the observations at Stanford, demonstrated that MDA-MB-435 behaved like melanoma because it likely was melanoma—in particular, a skin-cancer cell line called M14.
As word spread, Michael D. Johnson of Georgetown University Medical Center and a team of colleagues tested stocks of MDA-MB-435 from their lab and others around world. He said the group assumed their laboratory cell lines were the “real ones,” and that other scientists’ lines had been corrupted. Instead, the group found every one of the cell lines tested was melanoma, not breast cancer.
Decades of research had been built on insights from research using that cell line. Now, said Dr. Johnson, “I’m not going to use them to study breast cancer. I don’t believe they are breast cancer.”

Dr. Tarin disagrees, citing his own study that showed breast cancer tumours can have melanoma-like genes.
Increasingly, medical journals won’t accept research on breast cancer involving the MDA-MB-435 cell line, throwing into question decades of experiments and innumerable published papers based on the line.
Seeking to solve the problem, a committee led by ATCC, a nonprofit group based in Manassas, Va., released guidelines this year to establish standards to authenticate cancer cell lines.
ATCC is working with the National Centre for Biotechnology Information, a branch of the National Institutes of Health, to establish a central repository and database of cell lines that have undergone genetic testing and whose origins can be verified.

The National Institutes of Health have, so far, not required cell line authentication as a condition of receiving federal grants. The NIH in 2007 called for more stringent peer-review when cell lines are used in papers submitted for publication. Journals of the American Association For Cancer Research now require authors to disclose how and when their cell lines were tested.
One challenge is getting scientists to acknowledge their cell line is contaminated. The prevailing attitude, according to researchers, is that the other lab’s cell line may be contaminated but not mine.
Osamu Tetsu, a head-and-neck cancer researcher at the University of California, San Francisco, did a study in 2009 that concluded all six known cell lines used by researchers studying adenoid cystic carcinoma were contaminated.
All of the work done on the rare cancer—published papers, research, drug studies—had been conducted with mislabeled cell lines, Dr. Tetsu concluded. He called the findings “catastrophic.”
Jeffrey Kaufman, executive director of the Adenoid Cystic Carcinoma Research Foundation, said the group lost about $150,000 on a project that had to be scrapped. He alerted Dr. Mandic, who had a lab perform STR profiling on his cell line, which came from a colleague, who got it from another scientist a decade earlier. Tests revealed it was Ms. Lack’s cervical-cancer cell line.

The scientist cited in Dr. Tetsu’s paper as the source of one of the corrupted cell lines said his lab wasn’t responsible. Ruy Jaeger of the University of São Paulo in Brazil wrote in an email to The Wall Street Journal that his cell line was, in fact, adenoid cystic carcinoma. He also pointed out he had not directly provided the line used in the published paper.
Dr. Tetsu said he tested a cell line created from Dr. Jaegar’s line by a scientist in the U.S. The only way to resolve the dispute, said Dr. Tetsu, would be to perform STR profiling of Dr. Jaegar’s cells and compare them to the DNA of the original cancer patient.
The problem is particularly damaging for research into such rare cancers as adenoid cystic carcinoma, which strikes 1,200 people in the U.S. each year. The lack of a good cell line slows research and few in the field have the time or resources to create new lines.
More broadly, the sharing of cell lines is such an intrinsic part of scientific culture, Dr. Tetsu said, that “it is almost impossible to stop.”
University of Washington scientist Stanley Gartler warned about the practice in 1966. He had developed a pioneering technique using genetic markers that would distinguish one person’s cell from another. Using the process, he tested 20 of the most widely used cancer cells lines of the era. He found 18 of the lines weren’t unique: They were Ms. Lacks’ cervical cancer.

“People were upset,” said Dr. Gartler, who published his findings a year later in the journal Nature. “No one wants to admit they made a mistake.”
Dr. Gartler, an 88-year-old professor emeritus, said a decade after publication of his findings he attended a conference and introduced himself to a scientist. Dr. Gartler recalled the man told him, “‘I heard your talk on contamination. I didn’t believe what you said then and I don’t believe what you said now.’ ”
That became a long-held view. Nearly 40 years later, Dr. Masters, in a study of scientific papers published between 2000 and 2004, found nearly a 1,000 citations of the same contaminated cancer lines revealed in Dr. Gartler’s 1966 findings, which have since been replicated many times using more advanced techniques. “They are either crooks or stupid,” said Dr. Masters.
Financial donors to cancer research are unaware of the problem, Dr. Masters said, and “it would be a pity if money stopped going to cancer research” because scientists fail to test their cell lines, a procedure that costs about $200.

From San Diego, Dr. Tarin wrote to the ATCC to say his studies show that MDA-MB-435 is a breast cancer line, not melanoma. He has not heard back.
Yvonne Reid, who works for the ATCC and was a member of the committee that wrote the new guidelines, said, “It is hard to come down for one or the other” without testing tissue from the breast-cancer and melanoma patients who originated the cell lines.
Donald Morton, who was part of the team at the University of California, Los Angeles that in the 1980s grew the original melanoma line now believed to have contaminated MDA-MB-435, said his cell line has genetic markers that match the original patient with melanoma.
Dr. Morton, currently the melanoma program director at the John Wayne Cancer Institute in Santa Monica, Calif., said he would share frozen tissue samples from the melanoma patient with scientists seeking to test against contaminated cell lines.
His melanoma cells, Dr. Morton said, are indeed melanoma.
“What happened after that cell line left my lab,” he added, “I cannot say.”

Vitamin E analogues as a novel group of mitocans: Anti-cancer agents that act by targeting mitochondria

23rd Monday, 2012  |   Others  |  no comments

Mitochondria have recently emerged as new and promising targets for cancer prevention and therapy. One of the reasons for this is that mitochondria are instrumental to many types of cell death and often lie downstream from the initial actions of anti-cancer drugs. Unlike the tumour suppressor gene encoding p53 that is notoriously prone to inactivating mutations but whose function is essential for induction of apoptosis by DNA-targeting agents (such as doxorubicin or 5-fluorouracil), mitochondria present targets that are not so compromised by genetic mutation and whose targeting overcomes problems with mutations of upstream targets such as p53. We have recently proposed a novel class of anti-cancer agents, mitocans that exert their anti-cancer activity by destabilising mitochondria, promoting the selective induction of apoptotic death in tumour cells. In this communication, we review recent findings on mitocans and propose a common basis for their mode of action in inducing apoptosis of cancer cells. We use as an example the analogues of vitamin E that are proving to be cancer cell-specific and may soon be developed into efficient anti-cancer drugs. Source: Neuzil J, et al. Molecular Aspects of Medicine. Volume 28, Issues 5–6, October–December 2007, Pages 607–645

Progesterone Leads To Inflammation, A Breast Cancer Risk Factor, Research Reveals

23rd Monday, 2012  |   Breast Cancer  |  1 comment

Scientists at Michigan State University have found exposure to the hormone progesterone activates genes that trigger inflammation in the mammary gland. This progesterone-induced inflammation may be a key factor in increasing the risk of breast cancer. Progesterone is a naturally occurring steroid hormone and promotes development of the normal mammary gland. Progesterone previously has been identified as a risk factor for breast cancer, and in a study published in the Journal of Steroid Biochemistry and Molecular Biology, MSU scientists examined the genes activated by progesterone and the effects of their activation in a mouse model system. Exposure to progesterone in normal amounts and in normal circumstances causes inflammation, which promotes breast development. However, exposure to progesterone in menopausal hormone therapy is known to increase breast cancer risk. “Progesterone turns on a wide array of genes involved in several biological processes, including cell adhesion, cell survival and

inflammation,” said physiology professor Sandra Haslam, co-author of the paper and director of the Breast Cancer and the Environment Research Center at MSU. “All of these processes may be relevant to the development of breast cancer.” The study shows progesterone significantly regulates 162 genes in pubertal cells, 104 genes in adult cells and 68 genes at both developmental stages. A number of these genes make small proteins, called chemokines, which control the process of inflammation. Inflammation is a process where white blood cells move into a tissue. One type of white blood cell which moves to the breast during inflammation is a macrophage. Macrophages normally enter growing glands and help them develop, building blood vessels and reshaping growing tissue. “Macrophages also may promote the development of tumors, such as breast cancer, as they make blood vessels to deliver nutrients and can clear the way for tumors to grow,” Haslam said. “Long-term exposure to progesterone, such as that which occurs in menopausal hormone therapy, may encourage growth of tumors.” Haslam noted that as the link between progesterone and increased breast cancer risk was identified in recent years, women have been taking less hormone therapy after menopause and the rate of breast cancer in older women has gone down. “This study reveals the targets of a specific form of the progesterone receptor, called PRA, in mammary cell development,” said microbiology professor Richard Schwartz, a co-author of the paper and associate dean in the College of Natural Science. “The linkages identified provide targets for future work in reducing the influence progesterone has on developing breast cancer. “Understanding the genes that regulate inflammation in the mammary gland will help us to better understand normal breast growth and also may help us devise better treatments for the abnormal growth in cancer.” A collaborative team of 10 scientists in MSU’s departments of Physiology and Microbiology and Molecular Genetics contributed to the findings. The team’s work was published in the July 2009 issue of the journal. The team of faculty is part of MSU’s Breast Cancer and the Environment Research Center, one of four centers nationwide funded by the National Institute of Environmental Health Sciences and the National Cancer Institute. The center brings together researchers from MSU’s colleges of Natural Science and Human Medicine to study the impact of prenatal-to-adult environmental exposures that may predispose a woman to breast cancer, as well as researchers in the College of Communication Arts and Sciences to study how to best communicate breast cancer health messages to the public. Source: Jason Cody. (2009, August 21). “Progesterone Leads To Inflammation, A Breast Cancer Risk Factor, Research Reveals.” Medical News Today. Retrieved from

You are the only one who benefited from the president’s visit

22nd Sunday, 2012  |   Uncategorized  |  no comments

You are the one running for office Celine Replica, not the people of Peoria. You are the only one who benefited from the president’s visit. To promote a fundraiser for congressional candidate Aaron Schock has certainly caused some raised eyebrows in this area. Just two small questions. Firstly, with the supply chain for LEAP, can you give us a feel about the performance of your suppliers on that, particularly are they delivering to quality and to schedule so far, can you give us any feel for bottlenecks or issues and then the second question was on the long running topic of the commission’s inquiry brief, can you tell us if there has been any further communications from the commission Celine Replica, I presume you have responded to the questionnaire many months ago now. But it would be interesting to have an update on where that is, please?.

Replica Celine Bags Same goes for Illinois, which Celine Replica, like Ohio, votes on March 15. And Wisconsin on April 5. And Pennsylvania on April 26.” Read more.. Plans for Laurel Regional have sparked resentment from some in the community; they say area residents will have to travel too far for care. Some were caught off guard by the decision and questioned whether Dimensions’ management of the hospital was the real problem. Others wondered if Dimensions was cutting back at the Laurel hospital to focus on building a facility in conjunction with the University of Maryland Medical Center in Largo; an application is pending with the Maryland Health Care Commission.. Replica Celine Bags

Replica Celine LITTLE ROCK While the Ozark set family drama Winter’s Bone came up empty handed at the Oscars (it was nominated for multiple awards including Best Picture) Celine Replica Celine Replica, it won a couple of awards at the Independent Spirit Awards held Feb. 26. Dale Dickey and John Hawkes won awards for their supporting roles in the film.. Replica Celine

Celine Bags Cheap This battle was more fitting for the finale than an early battle. They were amazing throughout and had the judges on their feet. I think Christina made a mistake pitting these two against each other because she has to lose one. On Nov. 24. The museum is hosting an exhibit celebrating Sinatra’s upcoming 100th. Celine Bags Cheap

Cheap Celine Bags Replica A well known Internet blogger named Andrew Sullivan recently published a fine piece in New York magazine. It is titled I Used to Be a Human Being. He is a self described “manic information addict,” and his essay delves into what he calls his “distraction sickness.” He talks about how the once inconceivable pace of information consumption a constant Celine Replica, frenetic, unbridled barrage of images, click bait, news, propaganda and gossip has become the new normal in our Western culture Cheap Celine Bags Replica.

Cancer and the contribution of Complementary and Alternative Medicine (CAM)

19th Thursday, 2012  |   Others  |  no comments

A Round Table Meeting of the European Parliament Interest Groups MEPs Against Cancer and MEPs for CAM on the above topic took place on Tuesday 27th March 2012 in the European Parliament.
A European survey has shown that more than a third of cancer patients in Europe use complementary and alternative medicine (CAM), to increase their body’s ability to overcome the disease, to enhance their health and well?being, to feel empowered, and to alleviate physical and/or psychological distress.
Emerging evidence from scientific studies suggests that several CAM therapies may address pain, fatigue, and psychological distress and improve quality of life in cancer patients. Because of the growing interest in CAM by patients, academic cancer centres are exploring ways to integrate such care into a conventional cancer treatment system.
Prof. Dr. Dobos, Professor of Internal Medicine and Chair of Complementary and Integrative Medicine at the University of Duisburg-Essen Germany and Dr Madeleen Winkler, an experienced anthroposophic medical doctor and general practitioner from Gouda, in the Netherlands, (speaking on behalf of Prof. Dr Harald Matthes, Charité University Berlin, Germany) made presentations outlining the role of CAM in the prevention and treatment of cancer, and the benefits of integrating CAM and conventional approaches. Ms Heidi Brorson, a representative from the Norwegian Cancer Society and cancer league made a presentation on how they work with and advise cancer patients about using CAM as part of their cancer treatment plans.
MEPs Sirpa Pietikäinen of MEPs for CAM and Alojz Peterle representing MAC, the MEPs Against Cancer, co-chaired the meeting. They concluded the meeting with a call to the European Commission and the European Parliament to actively support the greater integration of CAM into the healthcare of EU citizens, particularly with regards to the prevention and treatment of cancer including empowerment of patients in self-care and to iron out inequalities in the use of CAM across Europe. They also called for greater investment in research into an integrated approach into the care and treatment of patients with cancer.